跳到正文
原文
Endpoints News 生物医药· Ryan Cross·· 2 天前AI 评分49

CTAD26:Biogen tau靶向药近两年用药后延缓阿尔茨海默病进展更显著

#CTAD26: Biogen’s tau drug slows Alzheimer’s more after nearly two years

AI 导读

在CTAD26会议上,Biogen报告其实验性阿尔茨海默病tau药物的数据似乎随用药时间延长而改善,最低剂量组的初步结果显示更长病程中疾病进展进一步减缓。

正文

BOSTON — The ben­e­fits of Bio­gen’s ex­per­i­men­tal Alzheimer’s drug seem to get bet­ter with time.
Over the sum­mer, Bio­gen re­port­ed that the low­est dose of its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news